Objective-The objective of this study was to investigate the effect of intravenous maternal sildenafil citrate (SC) administration on vascular function in growth-restricted fetal sheep. Approach and Results-Fetal growth restriction (FGR) results in cardiovascular adaptations that redistribute cardiac output to optimize suboptimal intrauterine conditions. These adaptations result in structural and functional cardiovascular changes, which may underlie postnatal neurological and cardiovascular sequelae. Evidence suggests SC, a potent vasodilator, may improve FGR. In contrast, recent clinical evidence suggests potential for adverse fetal consequence. Currently, there is limited data on SC effects in the developing fetus. We hypothesized that SC in utero would improve vascular development and function in an ovine model of FGR. Preterm lambs (0.6 gestation) underwent sterile surgery for single umbilical artery ligation or sham (control, appropriately grown) surgery to replicate FGR. Ewes received continuous intravenous SC (36 mg/24 h) or saline from surgery until 0.83 gestation. Fetuses were delivered and immediately euthanized for collection of femoral and middle cerebral artery vessels. Vessel function was assessed via in vitro wire myography. SC exacerbated growth restriction in growthrestricted fetuses and resulted in endothelial dysfunction in the cerebral and femoral vasculature, irrespective of growth status. Dysfunction in the cerebral circulation is endothelial, whereas smooth muscle in the periphery is the origin of the deficit. Conclusions-SC crosses the placenta and alters key fetal vascular development. Extensive studies are required to investigate the effects of SC on fetal development to address safety before additional use of SC as a treatment.
F
etal growth restriction (FGR) is the failure of a fetus to reach their genetic growth potential. 1 FGR is the second highest cause of perinatal death, complicating ≈5% to 10% of all pregnancies 2 and increasing stillbirth risk 20-fold. 3 After birth, FGR infants have an increased risk of both short-and long-term disease. 4 FGR most commonly occurs because of placental insufficiency, causing impaired placental blood flow and fetal hypoxia. In response to hypoxia, the fetus mounts a compensatory cardiovascular response to redistribute blood supply to important organs (eg, brain) at the expense of the periphery. 5 Despite the redistribution of blood flow, FGR infants are at greater risk of developing neurological and cardiovascular sequelae compared with their appropriately grown (AG) counterparts. 6 Brain-sparing is achieved via vasoconstriction of nonessential vascular beds, such as the periphery, this mechanism is initiated by chemoreflexes and sustained by reduced NO bioavailability. 7 Long-term chronic fetal hypoxia and persistent alteration in vascular resistance also cause vascular developmental deficits, such as increased thickening and stiffness of the aorta and carotid vessels and endothelial dysfunction, 8 an early marker of cardiovascular disease. 9 NO is produced by eNOS (endothelial NO synthase) located within the endothelial layers of blood vessels and is integral to local blood pressure control, acting as an endogenous vasodilator to mediate vascular diameter and blood flow. 10 It is well described that the FGR fetus has impaired NO-mediated vasodilation which can be attributed to NOS deficiency and decreased NO bioavailability. 9 Despite significant perinatal complications associated with FGR, there is currently no routine therapy to improve outcomes. Sildenafil citrate (SC) is a PDE (phosphodiesterase) 5 inhibitor which causes smooth muscle relaxation in blood vessels to increase vasodilation and subsequently, blood flow. SC has been proposed as a therapy in FGR pregnancies by acting to vasodilate placental blood vessels, which are abundant in PDE5, and increase placental blood flow. 11 In turn, improved placental blood flow is hypothesized to increase oxygen and nutrient transfer to the fetus, increasing fetal weight. Promising results from preclinical studies have underpinned a set of worldwide multicenter clinical trials involving the United Kingdom/Ireland, the Netherlands, Australia/New Zealand, and Canada. The Sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction (STRIDER) consortium aimed to determine if maternal SC treatment increases gestation length, placental function, and fetal growth. 14 Although results from some countries have now been reported and show no benefit of SC (AusNZ), the Dutch STRIDER was recently terminated before completion because of increased neonatal mortality in SC-treated infants compared to control. 15 Maternally-administered SC crosses the placenta into the fetal circulation, 16 where SC has potential to mediate direct cardiovascular effects. We and others have demonstrated dysfunction of the NO pathway in FGR when compared to AG. 17, 18 Therefore, given the vascular adaptations associated with FGR, predisposition toward endothelial dysfunction and the NO-mediated mechanism of SC action, we think investigation into potential fetal effects of SC exposure is a critical unknown. Herein, we utilized our established ovine model of FGR, which involves single umbilical artery ligation (SUAL) to determine fetal effects of maternal sildenafil administration. SUAL results in placental atrophy, subsequent reduction of placental function and the induction of clinical FGR features (decreased weight, brain-sparing). 19 We aimed to investigate the effect of maternal SC treatment on fetal vascular structure and function in growth-restricted fetuses. We hypothesized that maternal SC crosses the placenta into the fetal circulation, improves fetal growth, and results in functional improvement of NO-mediated vasodilation within the peripheral vasculature.
Materials and Methods
Experiments were approved by the Monash Medical Centre animal ethics committee (MMCA2016/01) in accordance with guidelines established by the National Health and Medical Research Council of Australia.
Animals
Twin bearing Border-Leicester pregnant ewes (n=13) underwent surgery on day 88 to 90 days gestation (term approximately 148 days gestation) to induce severe, early-onset FGR via SUAL, as previously described. 19 Previous studies by our group have investigated differences between early (89 days) and late (105 days) SUAL and have found that early SUAL resulted in increased FGR and brainsparing. 19 As criteria for the STRIDER was diagnosis of early and severe FGR, 20 we chose to use the early SUAL model in the current study. Briefly, anesthetized ewes underwent surgery in which 1 fetus (randomly selected) underwent SUAL to induce FGR. The umbilical cord of the twin fetus was manipulated but not ligated (control, AG). The fetuses were returned to the uterus, and catheters inserted into a maternal jugular vein for antibiotic and treatment administration and a carotid artery for blood sampling.
Experimental Procedures
Antibiotics were administered to the ewe (Ampicillin, 1g and Engemycin 5mL IV) for 3 days after surgery via the maternal jugular vein catheter.
Maternal Sildenafil/Saline Administration
On day 3 postsurgery, after completion of the antibiotics regimen, ewes were randomized to receive either SC (n=7, 36 mg/d) or saline (n=6) infusion via a pump (CADD-Legacy 1 Pump; Smiths Medical, Australia) connected to the maternal jugular vein catheter and fastened to the back of the ewe under netting. Twin fetuses within the ewes were subsequently randomized into groups; FGR and AG or SC-treated FGR (FGR SC ) and SC-treated AG (AG SC ). SC and saline administration occurred continuously for ≈5 weeks until postmortem (126 days gestation). This treatment regimen was used to reflect the dose chosen and used in the STRIDER trial.
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Postmortem
At 126 days gestation, fetuses from all groups were euthanized via pentobarbital sodium overdose to the ewe (100 mg/kg IV 153 Valabarb; Jurox, Rutherford, Australia). Third-order middle cerebral arteries (MCA) and femoral arteries (FEM) were carefully and immediately dissected for functional assessment (in vitro wire myography, see below).
Soluble Guanylate Cyclase Protein Level
sGC (soluble guanylate cyclase) is an enzyme present in smooth muscle cells and converts GTP into active cGMP. cGMP is the key intracellular molecule that is ultimately responsible for smooth muscle relaxation and subsequent vasodilation. We quantified sGC protein levels via Western blot.
Snap-frozen femoral vessel samples were homogenized in 0.1M Tris/HCL lysis buffer with 0.5% Triton X with 10 µL/mL phenylmethylsulphonyl fluoride. Total protein content of the supernatant was determined via the Lowry method using a Bio-Rad DC (detergent compatible) Protein Assay kit (Bio-Rad, CA). Protein samples (30 µg) in 4x sodium dodecyl sulfate (SDS) sample buffer (EMD Millipore, CA) were heat denatured, separated using 10% SDS-PAGE, and transferred to nitrocellulose membrane (Protran BA-85 nitrocellulose membrane, Schleicher and Schuell, Germany). Membranes were then incubated in primary antibody (rabbit antisGCb1 antibody, 1:500; Cayman or b-actin 1:1000, Cell Signalling Technologies) with 5% skim milk block overnight at 4°C. The protein was then detected by goat anti-rabbit IgG-HRP, 1:10,000 (Santa Cruz Biotechnology), and visualized with Chemiluminescence reagent LumiGLO (Cell Signalling Technologies, Danvers, MA) using Chemidoc XRS (Biorad, CA). The membrane image was analyzed using ImageJ analysis software. 21 The protein expression level was calculated from the average density of the sGC band divided by the average density of the beta-actin band.
In Vitro Wire Myography
Wire myography allows for the interrogation of vascular response and reactivity to vasoactive agents. 22 Third-order MCA and FEM 23 Initial contractile capacity was assessed in response to potassium (K+) physiological saline (0.12 M), and endothelial vasodilation ability was assessed with acetylcholine (Sigma A6625; Sigma-Aldrich). Collection and mounting of 2 mm dissections were repeated until viability of the vessel was determined via response to K+ solution and acetylcholine.
Assessment of Atrial Vasodilation Via Myography
Wire-mounted arteries were preconstricted with K + physiological saline (0.6M). K + physiological saline allowed for assessment of smooth muscle contractility and subsequent assessment of vasodilation of both MCA and FEM arteries in response to acetylcholine (Sigma A6625, 10 -10 -4 mol/L; Sigma-Aldrich). Response to drugs was performed via a similar method. After plateau of a submaximal contractile response from vasodilator, an initial dose was added to the bath to a concentration of 10 -10 mol/L or 10 -9 mol/L depending on the curve. Vessels were then exposed to progressively higher concentration (increased by a factor of 10 with each administration) until a final bath concentration of 10 -4 mol/L was achieved. SNP, acetylcholine, and sildenafil bath concentration was increased after plateau. Vasodilation response curves were performed on the same vessel. Vessels were rested at baseline for 20-minute rest between each response curve.
Average force exerted by the artery during each incubation was recorded. Individual results were averaged for drug concentration to create dose-response dilation curves. Relaxation curves were analyzed using an agonist line of best-fit assessments to determine overall maximal relaxation (%Rmax) and sensitivity (half-maximal effective concentration [pEC 50 ]).
The contribution of PDE5 to vasodilation within the MCA was calculated by subtracting the area under the curve in response to SC from the area under the curve in response to acetylcholine.
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Plasma Sildenafil Measurement
Maternal plasma samples were collected on alternate days from day 1 postsurgery until postmortem. In a subgroup of animals exposed to SC treatment, fetal plasma samples were collected at postmortem. Approximately 1 microliter of plasma samples were collected and analyzed for SC concentration via liquid chromatography-mass spectrometry by Thermo Fisher Australia using a protocol established by Vos et al. 25 SC is a PDE 5 inhibitor, which blocks the breakdown of cGMP to GMP in blood vessels. Increased intracellular smooth muscle cGMP mediates effects on downstream pathways to ultimately cause decreased vascular resistance, 26 increased vasodilation, and subsequently, increased blood flow.
Statistical Analysis
Data are for animal weight, ratios and sildenafil concentration presented as mean±SD. Data for myography analysis are presented as mean±SEM. Maximal contraction to high K + was analysed using a 1-way ANOVA, and a Tukey post hoc test was used to compare between groups (Prism 7 for Mac OS X, GraphPad Software). Body weight and brain to body weight ratio were analysed using a 2-way ANOVA and Tukey post hoc test to compare differences between groups. Myography results from isolated MCA and FEM were analysed using a 2-way repeated measures ANOVA and Tukey post hoc test was used to compare between groups or doses. Normality was calculated using D'Agostino and Pearson and Kolmogorov-Smirnov normality test (Prism 7 for Mac OS X, GraphPad Software).
Results
Plasma Sildenafil Concentrations
Maternal intravenous infusion of SC resulted in detectable levels of SC within fetal (3.05±1.50 pg/µL) and maternal (16.72±3.56 pg/µL) plasma (Table) . SC was undetectable in untreated animals (data not shown).
Fetal Birthweight and Brain: Body Weight
Comparisons were made between saline-treated AG (n=7) and FGR (n=6) fetuses and SC-treated AG SC (n=5) and FGR SC (n=6) fetuses, Table. One FGR and 1 AG SC fetus were not included in analysis because of complications after surgery. Fetal birthweight shows SUAL resulted in a 25% reduction in birth weight compared with AG (P=0.03). Surprisingly, treatment with SC exacerbated FGR resulting in a ≈50% reduction in birth weight compared with AG (P<0.001). No significant difference in birthweight was seen between saline-treated and AG SC fetuses. Brain weight was similar between saline-treated and AG SC fetuses but significantly lower in FGR SC compared with AG control. Brain/body weight ratio was significantly increased in FGR SC compared with AG, P=0.003 and AG SC, P=0.0024. No other significant differences in brain/body weight were seen between groups.
Myography Analysis
Arterial Contractile Ability Maximal contraction to high potassium solution (0.6M) was not different in the MCA between any groups ( Figure 1A ). In contrast, in the FEM maximal contractile force was significantly reduced (P<0.05) in FGR, FGR SC , and AG SC groups compared with AG fetuses ( Figure 1B Weights and SC concentration are mean±SD. Data were compared using a 2-way ANOVA to determine difference between treatments. Multiple comparisons were performed via a Tukey test. AG indicates appropriately grown; AGsc, SC-treated appropriately grown; FGR, fetal growth restriction; FGRsc, SC-treated fetal growth-restricted; and SC, sildenafil citrate. *Signifies significant difference (P<0.05) compared with AG. groups ( Figure 4B ). %Rmax was significantly impaired in AG SC and FGR SC vessels compared with saline-treated groups. %Rmax was significantly lower in AG SC and FGR SC compared with saline-treated ( Figure 4B , P<0.001). No difference in pEC50 and %Rmax was seen within treatment groups. Femoral vascular sensitivity (pEC 50 ) to SNP was significantly lower in SC-treated lambs compared with control ( Figure 4C ; P=0.0255). %Rmax was significantly greater in control lambs compared with SC treated (Figure 4C ; P>0.001). Femoral vascular sensitivity (pEC 50 ) to acetylcholine was not different between groups. Femoral %Rmax to acetylcholine (%Rmax) was significantly greater in control lambs compared with SC treated (Figure 4D ; P>0.001). No difference in pEC50 and %Rmax was seen within treatment groups.
Contribution of cGMP to Relaxation
To determine the relative contribution of cGMP to overall relaxation, PDE5 inhibitor SC was used. These data reveal a significantly greater cGMP capacity of sildenafil-treated fetuses compared with saline-treated fetuses (P=0.0059; Figure 5 ).
Protein Levels of Soluble Guanylate Cyclase
Protein levels of sGC within the FEM were not different between groups (data not shown).
Discussion
FGR increases the risks of long-term dysfunctions. 27 There is no cure for FGR; however, maternal administration of SC has suggested improvement in some animal studies of FGR [28] [29] [30] and in small human trials. 12, 31 In turn, SC has been the subject of the worldwide STRIDER clinical trial as a potential therapy for FGR. However, reports suggest that antenatal SC may increase mortality for the growth-restricted infant after birth. 15 There is currently limited data to show effects of SC on the already compromised cardiovascular structure and function in the setting of FGR. Assessment of vascular contractile ability is indicative of vascular health, integrity and can inform of potentially dysfunctional vascular pathways. 32 In the current study, we have validated the transfer of SC from the maternal circulation into the fetal circulation. Furthermore, we show that maternal SC administration exacerbated growth restriction and results in vascular dysfunction in the developing peripheral and cerebral cardiovascular system of FGR and AG fetuses. These differences are important. It has long been demonstrated that homeostasis within the peripheral vascular system is vital for blood pressure control. Of equal concern is dysfunction in the cerebral circulation, wherein exposure to SC caused endothelial dysfunction of cerebral vessels in FGR fetuses, which has implications for the brain-sparing adaptation mounted by the growth-restricted fetus, and acute cerebral responses to challenges after birth.
SC has been used clinically for many years. SC is a PDE 5 inhibitor with various applications, including erectile dysfunction (Viagra) and persistent pulmonary hypertension of the newborn. 33 SC induces vasodilation through the NO-cyclic cGMP pathway. PDE5 regulates intracellular levels of cGMP by hydrolyzing cGMP to GMP. Modulation of cGMP levels is critical for basal vascular tone and reactivity, where PDE5 promotes increased breakdown of cGMP and, therefore, vasoconstriction. SC inhibition of PDE5 thus promotes vasodilation. Animal and human studies have shown that SC crosses the placenta to enter the fetal circulation. 16 Itani et al have demonstrated protective cardiovascular effect of SC in hypoxic chicken embryos. 34 Although this study did not demonstrate an increase in fetal growth, SC treatment prevented oxidative stress, enhanced NO bioavailability, and restored peripheral endothelial function. 34 Our study is the first to demonstrate SC crosses the ovine placenta. SC concentrations of 3.5 nmol/L is considered clinically relevant and has the ability to inhibit 50% of PDE5 activity. 35 The difference in fetal to maternal SC concentrations is likely because of limitations in ovine placental transfer. However, the dose given to ewes resulted in fetal SC concentrations sufficient to inhibit >50% of fetal PDE5 activity.
Exacerbation of FGR
An unexpected but striking observation of this study is the exacerbation of FGR in fetal sheep after SC treatment. In this study, as in previous studies, SUAL resulted in asymmetrical growth restriction. 19 Antenatal SC exacerbated body weight deficits in FGR, resulting in a 49% reduction in FGR SC compared with AG fetuses, a finding accompanied by brain-sparing in FGR SC fetuses. No other studies have reported such striking decreases in body weight, but not all studies describe improved body weight. Although rodent studies have demonstrated increased fetal body weight, 13 other human and sheep studies do not show improvement in body weight. 36, 37 The mechanisms underlying increased growth restriction were not interrogated in this study, but it is likely that maternal hemodynamics play a central role. Miller et al 38 previously found maternal SC administration to ovine pregnancies complicated by FGR had the potential to cause detrimental uteroplacental flow. This study also reported fetal hypotension and tachycardia after maternal SC treatment. 38 It is important to note that although decrease in body weight in AG SC compared with AG lambs was not significant, body weights were ≈900g lighter and similar to that of FGR. We speculate that the reduction in body weight observed in both SC-treated groups may have occurred in either 1 or a combination of 2 ways:
The proposed mechanism of benefit of SC is through the increase in vasodilation of the placental vasculature and subsequent increase in blood flow. As previously discussed, our model recreates FGR through SUAL, which results in subsequent atrophy to half the placental surface area. 39 In our study, we think that any increase in blood flow by SC could only supply the still functional placenta regions. It is unknown if SC has the ability to repair malformed blood vessels and, therefore, in the context of impaired spiral artery remodeling, should similar placental vasodilation occur clinically, benefit of SC will also be limited. Given the observed reduction in fetal size after SC treatment seen in this study, we think that caution surrounding SC treatment is warranted. It is possible that long-term maternal SC administration may lead to chronic peripheral vasodilation within the maternal circulation, resulting in shunting of blood away from the fetoplacental circulation, further diminishing placental perfusion. Though not assessed in the current study, the increased abnormality in ductus venosus a-wave (UK STRIDER) may support our finding. 36 Reversal of flow through the ductus venosus may occur because of a decrease in pressure driven by vasodilation of the maternal and placental circulation.
Vascular Effects of FGR and SC
To interrogate vascular function, we measured vascular ability to constrict to K+, endothelial-mediated vasodilation using acetylcholine-mediated and smooth muscle-mediated vasodilation using SNP. We chose to investigate central and peripheral vascular beds because these are believed to be spared (MCA-central) and nonspared (femoral-peripheral) from the vascular consequences of FGR. FGR-associated endothelial dysfunction in the periphery is well described and found to be NO dependent, 9 with restoration possible via treatment with antioxidants such as vitamin C 40 and melatonin. 41 Additionally, Itani et al 41 show cardiovascular protection in chicken embryos after SC, suggesting potential benefit of SC treatment. FGR is associated with heterogeneous vascular remodeling in FGR offspring, where central vessels are favored or less affected compared with the vasculature of peripheral organs. 42 Our findings also support this study as FGR alone did not alter vascular responses in the cerebral circulation.
Sildenafil treatment impaired endothelial-mediated vasodilation in the MCA but enhanced the smooth muscle mediated vasodilation. The difference in response may be because of potential compensatory mechanisms in the NO pathway of the MCA smooth muscle after SC exposure. Increased sensitivity to SNP after SC treatment is indicative of developmental resetting of the NO pathway. This compensation was not observed in the peripheral circulation. Renshall et al 43 have also previously shown impaired endothelium-dependent and endothelium-independent vasodilation in SC-treated FGR mouse aorta, considered to be a central vascular bed. As both 50 and %Rmax of MCA in response to SNP and ACh (A and B, respectively) and FEM in response to SNP and ACh (C and D, respectively) of appropriately grown (AG, white, n=7), fetal growth-restricted (FGR, black, n=6), sildenafil citrate-treated AG (AG SC , gray, n=5) and sildenafil citrate-treated FGR (dark gray, n=6). Data were compared using a 2-way ANOVA. *Signify significant difference between treatments (P<0.05). SAL indicates saline.
direct administration of NO to the smooth muscle and inhibition of cGMP degrader, PDE5, resulted in enhanced vasodilation, it is clear that the vascular smooth muscle is intact. In contrast, endothelial-dependent vasodilation is nearly entirely attenuated; thus, SC administration is having its effects within the endothelium, likely because of decreased NO bioavailability or altered agonist receptor population. The potential cerebrovascular dysfunction may be described as a decrease in endothelial function and vascular reactivity observed in both FGR and AG following SC exposure. These results are concerning as they suggest exposure to SC in utero, rather than placental insufficiency, results in endothelial dysfunction. Interestingly, Kruuse et al 44 found that MCA from adult rats do not vasodilate to SC administration.
The maintenance of cerebral blood flow in FGR is a welldescribed response in FGR 45 ; further studies by Poudel et al 46 have shown that carotid blood flow between FGR and AG lambs is similar, despite increased systemic vascular resistance. We have furthered these findings to show that there is little difference in vasodilation of MCA between FGR and AG fetuses in our current study. Thus during brain-sparing, blood vessel function within spared beds is not altered.
However, despite attempts at maintaining cerebral perfusion, the FGR brain is susceptible to injury after FGR. 19 Given this, the diminished functionality of the cerebral vasculature following SC exposure is concerning, considering impaired autoregulation is associated with an increased risk of brain injury. 47 Further studies to interrogate mechanism on how antenatal SC exposure alters cerebrovascular development, and potential long-term effects, would provide greater insight to chronic SC exposure during pregnancy.
Although in the dysfunction in the cerebral vasculature are endothelial in origin, in the femoral vascular bed, SC administration decreased the vasodilatory response of the vascular smooth muscle to SNP, a NO donor that binds to sGC to cause vascular relaxation. Vascular smooth muscle relaxation occurs as a result of decreased intracellular calcium, and there are numerous pathways, such as the adenylate cyclase-cGMP pathway, which also play a role in vasodilation. In the current study, we focused on activation of sGC, but it is also possible that other pathways may be upregulated following antenatal treatment with SC. We observed that SC treatment impaired fetal peripheral smooth muscle function resulting in endothelial dysfunction. Although the peripheral vascular effects may result from fetal exposure to SC per se, it is also possible that a worsening of growth restriction may contribute to peripheral vascular deficits. Endothelial dysfunction is a well-established consequence of FGR, 41 the exacerbation of FGR observed in our study is of particular importance to vascular function.
PDE5 inhibition has been associated with smooth muscle preservation 48 and may explain the increased sensitivity to SNP observed in MCA. However, in contrast drastically lower maximal constriction was observed in FGR peripheral vessels. These differences are likely because of the hemodynamic adaptations mounted during brain-sparing in FGR. Unexpectedly, similar responses were seen within the femoral of both SC-treated groups, regardless of growth status. These findings are concerning as they suggest that independent SC exposure during development has the ability to disrupt smooth muscle and K + channel activity. Studies investigating SC actions on pulmonary hypertension have shown that SC exposure reduces smooth muscle deposition 49 and has antiproliferative properties within the smooth muscle via the eNOS-NO-cGMP pathway. 50 The pathway of NO-mediated vasodilation within the smooth muscle involves several key mediators. cGMP causes smooth muscle relaxation, proliferation, and differentiation 51 and is broken down by PDE5, the target of SC action. We and others have shown that SC exposure increases cGMP levels. 52 Of particular importance to this study, increased levels of cGMP and cGMP elevating agents can suppress proliferation of smooth muscle. 53 The observed decrease in smooth muscle response seen in SC-treated fetuses supports the potential for cGMP to disrupt smooth muscle proliferation. Furthermore, although SC exposure increased cGMP contribution to vasodilation, overall dilation was reduced in SC-treated fetuses ( Figure 5B ). These data together support the hypothesis that SC treatment in utero reduces NO bioavailability. cGMP curves were only conducted in MCA vessels, and therefore it is not possible to extrapolate this data to the FEM.
Limitations
In this study, we aimed to mimic the human dose of SC administration given in the STRIDER trials. To provide a controlled administration of SC to the pregnant ewe, SC was given intravenously to the ewe. This is in contrast to the STRIDER trial in which SC was taken orally in 3 tablets over the course of the day. Thus, the exposure to SC is likely to be different between our study and the human trial. SC taken orally has a bioavailability of ≈41 % 54 ; thus in the current study, we gave a dose of 36 mg per day to replicate this level. Furthermore, we commenced SC treatment at 3 days after inducing placental insufficiency, which is rather early compared to the human situation in which placental insufficiency and chronic hypoxia are likely to be well progressed. The delay in response to SNP, Figure 5 . cGMP contribution to vasodilation of the middle cerebral artery (MCA). Data are mean±SEM area under the curve (AUC) of vasodilation of the MCA in appropriately grown (AG, white, n=7), fetal growth-restricted (FGR, black, n=6), sildenafil citrate-treated AG (n=5) and sildenafil citrate-treated FGR (n=6) fetuses. Data were compared using a 2-way ANOVA to determine difference between treatments and growth status. *Signifies significant difference (P<0.05). Multiple comparisons were performed via a Tukey test.
relative to that of acetylcholine within the MCA of control animals, may suggest alteration of MCA smooth muscle from our SUAL intervention. Future studies should aim at interrogating the NO-mediated signaling pathways in this vessel. We also do not have measurements of uterine flow in this study and future studies should aim at investigating the effect of long-term SC treatment on uterine flow to better allude to the increased FGR observed. Additionally, because of the low numbers used in these studies, it was not possible to separately analyze the effects of fetal sex.
Conclusions
Although previous animal studies have shown SC to improve growth in FGR, the current study did not support those findings. Rather, SC resulted in exacerbation of growth restriction and additionally was detrimental to vascular function. Cerebral vascular function is normally preserved in growth-restricted offspring due to brain-sparing, but here we show that antenatal SC exposure impaired vascular function in this vital vascular bed. In turn, this has significant implications for the infant after birth, potentially limiting cerebral vascular reactivity to acute challenge and increasing the risk of neurological compromise. This study shows specific effects of SC exposure on the developing cardiovascular system of the fetus, which may, in turn, have longer-term detrimental effects on cardiovascular health. SC crosses the ovine and human placenta and accordingly, we suggest that the safety of SC should be considered with long-term cardiovascular health of the offspring in mind.
